The Lactate–Lactylation Axis in Hepatocellular Carcinoma: Biological Functions, Tumor Microenvironment, and Therapeutic Implications
- 1Department of General Surgery Center
Abstract
Peng-Fei Cheng,1,2,* Yuan-Ming Qiang,1,2,* Yue-Yi Sun,1,2,* Yi-Bo Sun,1,2 Yabo Ouyang,1,2 Guang-Ming Li1,2 1Department of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 10071, People’s Republic of China; 2Clinical Center for Liver Cancer, Capital Medical University, Beijing, 10071, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yabo Ouyang, Email [email protected]; Guang-Ming Li, Email [email protected]: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with metabolic reprogramming, epigenetic dysregulation, and an immunosuppressive tumor microenvironment (TME) contributing to disease progression and treatment challenges. Despite recent advances, clinical outcomes are often limited by intrinsic and acquired resistance to targeted therapies and immunotherapies, underscoring an urgent need for additional therapeutic strategies. Emerging evidence suggests that lactate, traditionally regarded as a metabolic waste product, can act as a signaling metabolite and modulator of epigenetic regulation, with potential roles in HCC pathogenesis. This review synthesizes current findings on the lactate–lactylation axis and its potential contributions to malignant progression. We delineate how lactate accumulation and associated extracellular acidification may impair immune surveillance and therapeutic efficacy, and discuss how lactate can contribute to lysine lactylation (Kla), including through lactyl-CoA-dependent mechanisms. Histone and non-histone lactylation have been implicated in the regulation of gene expression and protein function in malignant and stromal cells, potentially influencing angiogenesis, immune evasion, metabolic adaptation, metastasis, and treatment responses. By integrating these molecular insights, we provide a framework for understanding metabolic–epigenetic crosstalk, while distinguishing findings supported directly by HCC studies from mechanisms inferred from other experimental contexts. We also discuss emerging strategies targeting lactate production, transport, and the enzymatic regulators of lactylation. Ultimately, this review outlines research priorities for evaluating combination therapies and candidate biomarkers, while emphasizing the need for further mechanistic validation in HCC and clinical evaluation of interventions targeting this axis.Graphical Abstract: Cell pathway diagram linking glycolysis, lactate transport, lactyl-CoA, lactylation and EGFR signaling.Cell schematic with a plasma membrane, cytoplasm and nucleus linking glucose uptake, glycolysis, lactate transport, lactyl CoA formation, protein lactylation and EGFR signaling. At the upper left membrane, glucose is shown outside the cell and enters through a transporter labeled GLUT. In the cytoplasm, glycolysis is drawn as a vertical sequence: HK2 leads to G6P, then to PEP, then PKM2 leads to pyruvate. Pyruvate connects to lactate through two labeled enzymes, LDHA and LDHB. Lactate is drawn as red circles with nearby text H plus. At the upper membrane center, lactate transport is shown between two transporters labeled MCT4 and MCT1, with curved arrows indicating movement across the membrane. Lactate in the cytoplasm connects by an arrow to Lactyl CoA, shown with a separate label CoA. Lactyl CoA branches to two labeled processes. One branch points left to No histone Lactylation and a boxed list of proteins: MOESIN, IGF2BP3, c MYC, AK2, TWIST1, Rab7A, ABCF1, CENPA, YAP, PRDX1, CCNE2, ASH2L. The other branch points to Histone Lactylation inside the nucleus, drawn as nucleosomes on DNA with circular labels Kla. Next to this, a box labeled Writers lists KAT2A, P300, CBP, AARS1, AARS2. A box labeled Erasers lists SIRT1, SIRT2, SIRT3, HDAC1, HDAC2, HDAC3. A label promoter is shown on the DNA. In the nucleus at right, two transcription factor labels, HIF-1a and C-MYC, sit on DNA. A dashed oval encloses target gene labels SLC2A1, SLC16A3, LDHA, PKM2, HK2. Additional connected gene labels below include MCM7, IRS1, NEDD4, NUPR1, HECTD2, B7-H3, PD-L1, NDRG1, ESM1. At the upper right membrane, EGFR connects to two signaling chains. One chain is PI3K to Akt to mTOR. The other chain is RAS to Raf to MEK to ERK. Along the bottom outside the cell, a region shows MCT4 and MCT1 near labels CAF and TAM, with lactate circles and H plus. A central inset labeled Ion Trapping shows dots moving toward a blood vessel and is paired with the text Chemotherapy resistance. At the lower right, a gauge labeled pH shows tick labels 6.0 and 6.5. Nearby, a label TCR is placed next to a cell labeled CTLs with a red prohibition sign. Another label GPR81 is placed next to receptors and the text, GPR81 signaling, Immunosuppression. A label Treg is shown with a red prohibition sign.Keywords: hepatocellular carcinoma, lactate, lactylation, tumor microenvironment, epigenetic regulation, therapeutic resistance
Related
- Polysaccharide-mediated modulation of gut microbiota and lysine lactylation: implications for tumor microenvironment remodeling and cancer immunotherapy
- Therapeutic potential of natural product polysaccharides in hepatocellular carcinoma: from microenvironment modulation to combination strategies
- Targeting Ferroptosis-Mediated Tumor Microenvironment Remodeling in Hepatocellular Carcinoma: Therapeutic Resistance and Clinical Translation
- Malignant remodeling of the bone marrow microenvironment in acute myeloid leukemia: mechanisms and therapeutic implications
- Immunosenescence in Aging and Cancer: Molecular Mechanisms, Tumor Microenvironment Remodeling, and Therapeutic Implications
BibTeX
@article{cheng2026lactatendashlactylation,
title = {{The Lactate–Lactylation Axis in Hepatocellular Carcinoma: Biological Functions, Tumor Microenvironment, and Therapeutic Implications}},
author = {Cheng PF and Qiang YM and Sun YY and Sun YB and Ouyang Y and Li GM},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
month = nov,
url = {https://www.dovepress.com/the-lactatelactylation-axis-in-hepatocellular-carcinoma-biological-fun-peer-reviewed-fulltext-article-JHC},
note = {CC BY},
}
RIS
TY - JOUR
TI - The Lactate–Lactylation Axis in Hepatocellular Carcinoma: Biological Functions, Tumor Microenvironment, and Therapeutic Implications
AU - Cheng PF
AU - Qiang YM
AU - Sun YY
AU - Sun YB
AU - Ouyang Y
AU - Li GM
PY - 2026
DA - 2026/11/15
JO - Journal of Hepatocellular Carcinoma
UR - https://www.dovepress.com/the-lactatelactylation-axis-in-hepatocellular-carcinoma-biological-fun-peer-reviewed-fulltext-article-JHC
AB - Peng-Fei Cheng,1,2,* Yuan-Ming Qiang,1,2,* Yue-Yi Sun,1,2,* Yi-Bo Sun,1,2 Yabo Ouyang,1,2 Guang-Ming Li1,2 1Department of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 10071, People’s Republic of China; 2Clinical Center for Liver Cancer, Capital Medical University, Beijing, 10071, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yabo Ouyang, Email [email protected]; Guang-Ming Li, Email [email protected]: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with metabolic reprogramming, epigenetic dysregulation, and an immunosuppressive tumor microenvironment (TME) contributing to disease progression and treatment challenges. Despite recent advances, clinical outcomes are often limited by intrinsic and acquired resistance to targeted therapies and immunotherapies, underscoring an urgent need for additional therapeutic strategies. Emerging evidence suggests that lactate, traditionally regarded as a metabolic waste product, can act as a signaling metabolite and modulator of epigenetic regulation, with potential roles in HCC pathogenesis. This review synthesizes current findings on the lactate–lactylation axis and its potential contributions to malignant progression. We delineate how lactate accumulation and associated extracellular acidification may impair immune surveillance and therapeutic efficacy, and discuss how lactate can contribute to lysine lactylation (Kla), including through lactyl-CoA-dependent mechanisms. Histone and non-histone lactylation have been implicated in the regulation of gene expression and protein function in malignant and stromal cells, potentially influencing angiogenesis, immune evasion, metabolic adaptation, metastasis, and treatment responses. By integrating these molecular insights, we provide a framework for understanding metabolic–epigenetic crosstalk, while distinguishing findings supported directly by HCC studies from mechanisms inferred from other experimental contexts. We also discuss emerging strategies targeting lactate production, transport, and the enzymatic regulators of lactylation. Ultimately, this review outlines research priorities for evaluating combination therapies and candidate biomarkers, while emphasizing the need for further mechanistic validation in HCC and clinical evaluation of interventions targeting this axis.Graphical Abstract: Cell pathway diagram linking glycolysis, lactate transport, lactyl-CoA, lactylation and EGFR signaling.Cell schematic with a plasma membrane, cytoplasm and nucleus linking glucose uptake, glycolysis, lactate transport, lactyl CoA formation, protein lactylation and EGFR signaling. At the upper left membrane, glucose is shown outside the cell and enters through a transporter labeled GLUT. In the cytoplasm, glycolysis is drawn as a vertical sequence: HK2 leads to G6P, then to PEP, then PKM2 leads to pyruvate. Pyruvate connects to lactate through two labeled enzymes, LDHA and LDHB. Lactate is drawn as red circles with nearby text H plus. At the upper membrane center, lactate transport is shown between two transporters labeled MCT4 and MCT1, with curved arrows indicating movement across the membrane. Lactate in the cytoplasm connects by an arrow to Lactyl CoA, shown with a separate label CoA. Lactyl CoA branches to two labeled processes. One branch points left to No histone Lactylation and a boxed list of proteins: MOESIN, IGF2BP3, c MYC, AK2, TWIST1, Rab7A, ABCF1, CENPA, YAP, PRDX1, CCNE2, ASH2L. The other branch points to Histone Lactylation inside the nucleus, drawn as nucleosomes on DNA with circular labels Kla. Next to this, a box labeled Writers lists KAT2A, P300, CBP, AARS1, AARS2. A box labeled Erasers lists SIRT1, SIRT2, SIRT3, HDAC1, HDAC2, HDAC3. A label promoter is shown on the DNA. In the nucleus at right, two transcription factor labels, HIF-1a and C-MYC, sit on DNA. A dashed oval encloses target gene labels SLC2A1, SLC16A3, LDHA, PKM2, HK2. Additional connected gene labels below include MCM7, IRS1, NEDD4, NUPR1, HECTD2, B7-H3, PD-L1, NDRG1, ESM1. At the upper right membrane, EGFR connects to two signaling chains. One chain is PI3K to Akt to mTOR. The other chain is RAS to Raf to MEK to ERK. Along the bottom outside the cell, a region shows MCT4 and MCT1 near labels CAF and TAM, with lactate circles and H plus. A central inset labeled Ion Trapping shows dots moving toward a blood vessel and is paired with the text Chemotherapy resistance. At the lower right, a gauge labeled pH shows tick labels 6.0 and 6.5. Nearby, a label TCR is placed next to a cell labeled CTLs with a red prohibition sign. Another label GPR81 is placed next to receptors and the text, GPR81 signaling, Immunosuppression. A label Treg is shown with a red prohibition sign.Keywords: hepatocellular carcinoma, lactate, lactylation, tumor microenvironment, epigenetic regulation, therapeutic resistance
SN - 2253-5969
ER -